Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
Sponsor: AstraZeneca
Summary
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). The Phase III part of the study will no longer be conducted.
Official title: A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2025-07-28
Completion Date
2027-01-29
Last Updated
2026-08-03
Healthy Volunteers
No
Conditions
Interventions
Volrustomig
Volrustomig will be administered as an intravenous (IV) infusion.
Casdatifan
Casdatifan will be administered orally.
Locations (3)
Research Site
Elizabeth Vale, Australia
Research Site
Busan, South Korea
Research Site
Seoul, South Korea